CNBC's Julia Boorstin weighs in on Microsoft's acquisition of LinkedIn.
Ivan Feinseth, Tigress Financial Partners, explains why he thinks Microsoft's acquisition of LinkedIn is a "step in the right direction." Also Feinseth weighs in on Twitter.
Microsoft is buying social media company LinkedIn in an all cash deal for $26.2 billion. CNBC's Jon Fortt weighs in.
Microsoft is buying social media company LinkedIn in an all cash deal for $26.2 billion.
Giuseppe Lavazza, vice-chairman of coffee maker Luigi Lavazza, discusses his company's recent spree of acquisitions.
André Hoffmann, non-executive vice-chairman of pharma company Roche Holding, says few mergers have created a better company.
Ben van Beurden, CEO of Royal Dutch Shell, says there are about $1 billion of extra synergies to be achieved from the acquisition of BG Group.
AT&T put in a bid for Yahoo's core business and is still in the race, according to a Bloomberg report citing sources.
Dennis Gartman, founder, editor & publisher of The Gartman Letter, comments on Monsanto's decision to reject the Bayer acquisition proposal.
Paul Speaker, World Surf League, talks about champion surfer Kelly Slater, and the growing popularity of digitized surfing.
Telecom network equipment maker Nokia may cut 10,000 to 15,000 jobs as part of a cost-cutting programme, a union representative said.
John Rountree, managing partner at Novasecta, talks about whether or not the Bayer-Monsanto merger would create more or less innovation and value.
Scott Moeller, director of the M&A Research Centre at Cass Business School, and John Rountree, from Novasecta, discuss the Bayer-Monsanto deal.
Werner Baumann, Bayer CEO, weighs in on the tax ramification of the combined companies.
Werner Baumann, Bayer CEO, explain why he went public with the $62 billion bid for Monsanto.
CNBC's Nancy Hulgrave reports on Bayer's big move to create a global leader in agriculture.
Julien Jarmoszko, senior research manager at S&P Global Market Intelligence, talks about Bayer's decision to acquire Monsanto.
Werner Baumann, Bayer CEO, explains why he thinks the company's offer for Monsanto would likely pass regulatory scrutiny and doesn't see risk in the deal.
The pharmaceutical company Bayer has announced plans to acquire American biotech company Monsanto, making an all cash offer of $122 per share.
Ashok Shah, director of London & Capital, says to expect more large mergers and acquisitions in the months to come due to the low cost of capital.